001     139938
005     20210129212726.0
024 7 _ |a 10.1111/bph.12118
|2 doi
024 7 _ |a 0366-0826
|2 ISSN
024 7 _ |a 1476-5381
|2 ISSN
024 7 _ |a 0007-1188
|2 ISSN
024 7 _ |a WOS:000317679000011
|2 WOS
024 7 _ |a 2128/5643
|2 Handle
037 _ _ |a FZJ-2013-05905
082 _ _ |a 610
100 1 _ |a Watkins, HA
|0 P:(DE-HGF)0
|b 0
245 _ _ |a Identification of key residues involved in adrenomedullin binding to the AM 1 receptor
260 _ _ |a Malden, MA
|c 2013
|b Wiley
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 139938
|2 PUB:(DE-HGF)
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|0 0
|2 EndNote
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a article
|2 DRIVER
500 _ _ |3 POF3_Assignment on 2016-02-29
520 _ _ |a BACKGROUND AND PURPOSE:Adrenomedullin (AM) is a peptide hormone whose receptors are members of the class B GPCR family. They comprise a heteromer between the GPCR, the calcitonin receptor-like receptor and one of the receptor activity-modifying proteins 1-3. AM plays a significant role in angiogenesis and its antagonist fragment AM22-52 can inhibit blood vessel and tumour growth. The mechanism by which AM interacts with its receptors is unknown.EXPERIMENTAL APPROACH:We determined the AM22-52 binding epitope for the AM1 receptor extracellular domain using biophysical techniques, heteronuclear magnetic resonance spectroscopy and alanine scanning.KEY RESULTS:Chemical shift perturbation experiments located the main binding epitope for AM22-52 at the AM1 receptor to the C-terminal 8 amino acids. Isothermal titration calorimetry of AM22-52 alanine-substituted peptides indicated that Y52, G51 and I47 are essential for AM1 receptor binding and that K46 and P49 and R44 have a smaller role to play. Characterization of these peptides at the full-length AM receptors was assessed in Cos7 cells by cAMP assay. This confirmed the essential role of Y52, G51 and I47 in binding to the AM1 receptor, with their substitution resulting in ≥100-fold reduction in antagonist potency compared with AM22-52 . R44A, K46A, S48A and P49A AM22-52 decreased antagonist potency by approximately 10-fold.CONCLUSIONS AND IMPLICATIONS:This study localizes the main binding epitope of AM22-52 to its C-terminal amino acids and distinguishes essential residues involved in this binding. This will inform the development of improved AM receptor antagonists.
536 _ _ |a 452 - Structural Biology (POF2-452)
|0 G:(DE-HGF)POF2-452
|c POF2-452
|f POF II
|x 0
588 _ _ |a Dataset connected to CrossRef, juser.fz-juelich.de
700 1 _ |a Au, M
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Bobby, R
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Archbold, JK
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Abdul-Manan, N
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Moore, JM
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Middleditch, MJ
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Williams, GM
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Brimble, MA
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Dingley, Andrew
|0 P:(DE-Juel1)145681
|b 9
700 1 _ |a Hay, DL
|0 P:(DE-HGF)0
|b 10
|e Corresponding author
773 _ _ |a 10.1111/bph.12118
|g Vol. 169, no. 1, p. 143 - 155
|0 PERI:(DE-600)2029728-2
|n 1
|p 143 - 155
|t British journal of pharmacology
|v 169
|y 2013
|x 0007-1188
856 4 _ |u http://www.ncbi.nlm.nih.gov/pubmed/23351143
856 4 _ |u https://juser.fz-juelich.de/record/139938/files/FZJ-2013-05905.pdf
|y OpenAccess
|z Published final document.
856 4 _ |u https://juser.fz-juelich.de/record/139938/files/FZJ-2013-05905.jpg?subformat=icon-144
|x icon-144
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/139938/files/FZJ-2013-05905.jpg?subformat=icon-180
|x icon-180
|y OpenAccess
856 4 _ |u https://juser.fz-juelich.de/record/139938/files/FZJ-2013-05905.jpg?subformat=icon-640
|x icon-640
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:139938
|p openaire
|p open_access
|p driver
|p VDB
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich GmbH
|0 I:(DE-588b)5008462-8
|k FZJ
|b 9
|6 P:(DE-Juel1)145681
913 2 _ |a DE-HGF
|b Key Technologies
|l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences
|1 G:(DE-HGF)POF3-550
|0 G:(DE-HGF)POF3-559H
|2 G:(DE-HGF)POF3-500
|v Addenda
|x 0
913 1 _ |a DE-HGF
|b Schlüsseltechnologien
|1 G:(DE-HGF)POF2-450
|0 G:(DE-HGF)POF2-452
|2 G:(DE-HGF)POF2-400
|v Structural Biology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF2
|l BioSoft
914 1 _ |y 2013
915 _ _ |a JCR/ISI refereed
|0 StatID:(DE-HGF)0010
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)ICS-6-20110106
|k ICS-6
|l Strukturbiochemie
|x 0
980 1 _ |a FullTexts
980 _ _ |a journal
980 _ _ |a UNRESTRICTED
980 _ _ |a FullTexts
980 _ _ |a I:(DE-Juel1)ICS-6-20110106
980 _ _ |a VDB
981 _ _ |a I:(DE-Juel1)IBI-7-20200312


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21